Advertisement
CRISPR Therapeutics Says FDA Grants RMAT Designation To CTX130
(RTTNews) - Biopharmaceutical company CRISPR Therapeutics (CRSP) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the Company's wholly-owned allogeneic CAR T cell therapy targeting CD70, for the treatment of Mycosis Fungoides and Sézary Syndrome (MF/SS).
Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising pipeline products, including genetic therapies.
Similar to Breakthrough Therapy designation, RMAT designation provides the benefits of intensive FDA guidance on efficient drug development.
For More Such Health News, visit rttnews.com
read more
Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology
Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) and gene editing company CRISPR Therapeutics, Inc. (CRSP) announced Monday that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics' gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex's hypoimmune cell therapies for type 1 diabetes (T1D).
RTTNews
|
875 ngày trước
TSX Down Marginally In Lackluster Trade
Canadian stocks are turning in a lackluster performance on Monday as investors closely focusing on the meeting between U.S. President Donald Trump and Ukrainian President Volodymyr Zelenskyy at the White House.
RTTNews
|
1h 1phút trước
Swiss Market Settles Flat
After a flat start, the Switzerland market turned weak Monday morning and then spent the rest of the day's trading session in negative territory as investors remained reluctant to pick up stocks as they looked ahead to a meeting between U.S. President Donald Trump and several European leaders to discuss the situation in Ukraine.
RTTNews
|
1h 27phút trước
European Markets Close On Mixed Note After Cautious Session
European stocks turned in a mixed performance on Monday as investors largely stayed cautious, looking ahead to the meeting between U.S. President Donald Trump and several European leaders, including Ukrainian President Volodymyr Zelenskyy after the Trump-Putin Summit failed to result in any breakthrough to end the war in Ukraine.
RTTNews
|
1h 45phút trước
Dollar Extends Losses As Markets Cling On To Fed Cut Hopes
The Dollar extended losses during the week ended August 15 amidst strong Fed rate cut expectations, benign consumer price growth, easing geopolitical concerns as well as fading concerns about trade tariff uncertainty.
RTTNews
|
4h 27phút trước
U.S. Homebuilder Confidence Edges Slightly Lower In August
The National Association of Home Builders released a report on Monday showing a modest deterioration by U.S. homebuilder confidence in the month of August. The report said the NAHB/Wells Fargo Housing Market Index edged down to 32 in August after inching up to 33 in July. Economists had expected the index to come in unchanged.
RTTNews
|
4h 39phút trước
Indian Rupee Rises To 2-week High On GST Reforms Push
The Indian rupee strengthened against the U.S. dollar in the European session on Monday, after Prime Minister Narendra Modi unveiled plans of the biggest tax overhaul since 2017 over the weekend, boosting stocks across sectors like auto, financial, real estate, consumer and cement.
RTTNews
|
6h 25phút trước
Canadian Market May Open Slightly Weak
Lower Canadian and U.S. futures and weak European markets point to a slightly negative start on Bay Street Monday morning. Firm commodity prices might help limit market's downside.
The focus will be on the meeting between U.S. President Donald Trump and several European leaders, including Ukrainian President Volodymyr Zelenskiy later in the day.
RTTNews
|
7h 0phút trước
